South Korea · Delayed Price · Currency is KRW KoBioLabs Statistics
Total Valuation
KoBioLabs has a market cap or net worth of KRW 73.40 billion. The enterprise value is 59.71 billion.
| Market Cap | 73.40B |
| Enterprise Value | 59.71B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
KoBioLabs has 19.42 million shares outstanding.
| Current Share Class | 19.42M |
| Shares Outstanding | 19.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 29.87% |
| Owned by Institutions (%) | 0.14% |
| Float | 13.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.03 |
| PB Ratio | 1.56 |
| P/TBV Ratio | 2.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.02 |
| EV / Sales | 0.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.12 |
Financial Position
The company has a current ratio of 3.91, with a Debt / Equity ratio of 0.35.
| Current Ratio | 3.91 |
| Quick Ratio | 3.30 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.60 |
| Interest Coverage | -18.42 |
Financial Efficiency
Return on equity (ROE) is -8.27% and return on invested capital (ROIC) is -8.44%.
| Return on Equity (ROE) | -8.27% |
| Return on Assets (ROA) | -5.89% |
| Return on Invested Capital (ROIC) | -8.44% |
| Return on Capital Employed (ROCE) | -11.74% |
| Weighted Average Cost of Capital (WACC) | 4.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.88 |
Taxes
In the past 12 months, KoBioLabs has paid 27.13 million in taxes.
| Income Tax | 27.13M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.75% in the last 52 weeks. The beta is 0.10, so KoBioLabs's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | -20.75% |
| 50-Day Moving Average | 5,071.30 |
| 200-Day Moving Average | 5,382.50 |
| Relative Strength Index (RSI) | 29.78 |
| Average Volume (20 Days) | 91,491 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KoBioLabs had revenue of KRW 71.21 billion and -3.73 billion in losses.
| Revenue | 71.21B |
| Gross Profit | 52.49B |
| Operating Income | -8.86B |
| Pretax Income | -4.08B |
| Net Income | -3.73B |
| EBITDA | -6.07B |
| EBIT | -8.86B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 47.08 billion in cash and 16.63 billion in debt, with a net cash position of 30.45 billion or 1,568.25 per share.
| Cash & Cash Equivalents | 47.08B |
| Total Debt | 16.63B |
| Net Cash | 30.45B |
| Net Cash Per Share | 1,568.25 |
| Equity (Book Value) | 46.99B |
| Book Value Per Share | 1,553.33 |
| Working Capital | 44.78B |
Cash Flow
In the last 12 months, operating cash flow was -2.57 billion and capital expenditures -396.12 million, giving a free cash flow of -2.97 billion.
| Operating Cash Flow | -2.57B |
| Capital Expenditures | -396.12M |
| Depreciation & Amortization | 2.79B |
| Net Borrowing | 766.72M |
| Free Cash Flow | -2.97B |
| FCF Per Share | -152.87 |
Margins
Gross margin is 73.71%, with operating and profit margins of -12.44% and -5.24%.
| Gross Margin | 73.71% |
| Operating Margin | -12.44% |
| Pretax Margin | -5.73% |
| Profit Margin | -5.24% |
| EBITDA Margin | -8.52% |
| EBIT Margin | -12.44% |
| FCF Margin | n/a |
Dividends & Yields
KoBioLabs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -5.08% |
| FCF Yield | -4.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KoBioLabs has an Altman Z-Score of -0.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.22 |
| Piotroski F-Score | 4 |